Envafolimab

Generic Name
Envafolimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2102192-68-5
Unique Ingredient Identifier
ES1M06M6QH
Indication

用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

First Posted Date
2024-10-29
Last Posted Date
2024-10-29
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
72
Registration Number
NCT06663007
Locations
🇨🇳

Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China

Local Injection and Systemic Therapy in the Treatment of NSCLC.

First Posted Date
2024-09-30
Last Posted Date
2024-09-30
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
84
Registration Number
NCT06618391

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

First Posted Date
2023-09-29
Last Posted Date
2023-10-11
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
33
Registration Number
NCT06060704
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

First Posted Date
2023-08-28
Last Posted Date
2024-04-12
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
55
Registration Number
NCT06014372
Locations
🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Not yet recruiting
Conditions
Epithelial Ovarian Cancer
Interventions
Drug: Envafolimab
First Posted Date
2023-08-24
Last Posted Date
2023-08-24
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
60
Registration Number
NCT06010667
Locations
🇨🇳

Hebei, Shijiazhuang, Hebei, China

Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer

First Posted Date
2023-08-01
Last Posted Date
2023-08-01
Lead Sponsor
池畔
Target Recruit Count
72
Registration Number
NCT05969847
Locations
🇨🇳

Pan Chi, Fuzhou, Fujian, China

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

First Posted Date
2023-07-12
Last Posted Date
2024-04-18
Lead Sponsor
Shanghai 6th People's Hospital
Target Recruit Count
20
Registration Number
NCT05941325
Locations
🇨🇳

Shanghai No.6 People Hospital, Shanghai, Shanghai, China

Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma

Phase 2
Recruiting
Conditions
Rectal Cancer
Interventions
Drug: Envafolimab
First Posted Date
2023-05-15
Last Posted Date
2023-05-15
Lead Sponsor
Sir Run Run Shaw Hospital
Target Recruit Count
30
Registration Number
NCT05858567
Locations
🇨🇳

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

First Posted Date
2023-04-25
Last Posted Date
2023-04-25
Lead Sponsor
Fujian Medical University Union Hospital
Target Recruit Count
33
Registration Number
NCT05828381
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy